TY - JOUR
T1 - Zoladex versus orchiectomy in treatmentof advanced prostate cancer
T2 - a randomized trial
AU - Soloway, Mark S.
AU - Smith, Joseph A.
AU - Chodak, Gerald
AU - Scott, Mark
AU - Vogelzang, Nicholas J.
AU - Kennealey, Gerald
AU - Block, Norman L.
AU - Gau, Timothy C.
AU - Schellhammer, Paul F.
PY - 1991/1
Y1 - 1991/1
N2 - We report preliminary results for the first 164 patients enrolled in a multicenter studycomparing the endocrine effects, efficacy, and safety of 3.6 mg of goserelin acetate (Zoladex) and orchiectomy in patients with Stage D2 prostate cancer. Eighty-one patients were randomly allocated to receive Zoladex and 83 to orchiectomy. The median follow-up time for all patients was two hundred ten days. Median serum levels of testosterone were reduced to castrate levels (< 50 ng/dL) within four weeks in both groups and remained suppressed for up to sixty weeks. An objective response according to modified criteria of the National Prostatic Cancer Project was observed in 81 percent and 78 percent of patients in the Zoladex and orchiectomy groups, respectively. There were no statistically significant differences between treatment groups in the distributions of time to treatment failure or time to disease progression. The most commonly reported adverse events in both treatment groups were hot flashes, cancer-related pain, unspecified pain, and urinary symptoms. These results suggest that Zoladex may offer an alternative to orchiectomy in the treatment of advanced prostate cancer.
AB - We report preliminary results for the first 164 patients enrolled in a multicenter studycomparing the endocrine effects, efficacy, and safety of 3.6 mg of goserelin acetate (Zoladex) and orchiectomy in patients with Stage D2 prostate cancer. Eighty-one patients were randomly allocated to receive Zoladex and 83 to orchiectomy. The median follow-up time for all patients was two hundred ten days. Median serum levels of testosterone were reduced to castrate levels (< 50 ng/dL) within four weeks in both groups and remained suppressed for up to sixty weeks. An objective response according to modified criteria of the National Prostatic Cancer Project was observed in 81 percent and 78 percent of patients in the Zoladex and orchiectomy groups, respectively. There were no statistically significant differences between treatment groups in the distributions of time to treatment failure or time to disease progression. The most commonly reported adverse events in both treatment groups were hot flashes, cancer-related pain, unspecified pain, and urinary symptoms. These results suggest that Zoladex may offer an alternative to orchiectomy in the treatment of advanced prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=0026021197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026021197&partnerID=8YFLogxK
U2 - 10.1016/0090-4295(91)80077-K
DO - 10.1016/0090-4295(91)80077-K
M3 - Article
C2 - 1824732
AN - SCOPUS:0026021197
VL - 37
SP - 46
EP - 51
JO - Urology
JF - Urology
SN - 0090-4295
IS - 1
ER -